TherVacB_Phase1a: Open Phase 1a Trial to Assess the Safety and Immunogenicity of a Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate in Healthy Volunteers

This study is an open-label, ascending dose phase 1a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine

Start Date23 Jan 2024

Sponsor / Collaborator

Universitätsklinikum Hamburg-Eppendorf

[+5]

NCT04843852

/ WithdrawnPhase 1IIT

Augmentation of Humoral Immunity Using Toll-Like Receptor (TLR) 9 Adjuvanted HBV Surface Antigen to Enhance Anti-HBSAg Response

Unmethylated cystine-guanosine dinucleotide (CpG) motifs are pathogen-associated molecular patterns (PAMPs) associated with bacterial and viral-derived DNA that activate the innate and humoral immunity via toll-like receptor 9. This is a randomized controlled pilot study evaluating the clinical and immune correlates of a seroprotective immune response against a CpG-adjuvanted vaccine for hepatitis B.

Start Date01 Jul 2022

Sponsor / Collaborator

University of Maryland Baltimore

NCT03664648

/ Active, not recruitingNot Applicable

HEPLISAV-B Pregnancy Registry: An Observational Study on the Safety of HEPLISAV-B Exposure in Pregnant Women and Their Offspring

Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy

Start Date21 Feb 2021

Sponsor / Collaborator

Dynavax Technologies Corp.

100 Clinical Results associated with Adjuvanted Hepatitis B vaccine (Recombinant)(Dynavax Technologies Corp.)

100 Translational Medicine associated with Adjuvanted Hepatitis B vaccine (Recombinant)(Dynavax Technologies Corp.)

100 Patents (Medical) associated with Adjuvanted Hepatitis B vaccine (Recombinant)(Dynavax Technologies Corp.)

Literatures (Medical) associated with Adjuvanted Hepatitis B vaccine (Recombinant)(Dynavax Technologies Corp.)

31 Dec 2024·Expert Review of Vaccines

Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses

Review

Author: Su, Xin ; Chen, Shiyun ; Liang, Xiaofeng ; Zeng, Fangfang ; Yan, Haoyu ; Huang, Haokun ; Zhu, Sui ; Cai, Jun ; Li, Jiaxin ; Wen, Huiyan ; Liu, Jiazi ; Huang, Shiqi ; Qiu, Jiamin ; Feng, Yonghui ; Diao, Zhiquan ; Zhang, Shiwen

BACKGROUNDThere is a lack of synthesis of literature to determine hepatitis B vaccine (HepB) strategies for hepatitis B virus (HBV) supported by quality evidence. We aimed to explore the efficacy and safety of HepB strategies among people with different characteristics.RESEARCH DESIGN AND METHODSPubMed, Cochrane Library, Embase, and Web of Science were searched for meta-analyses comparing the efficacy and safety of HepB up to July 2023.RESULTSTwenty-one meta-analyses comparing 83 associations were included, with 16 high quality, 4 moderate, and 1 low quality assessed by AMSTAR 2. Highly suggestive evidence supports HepB booster and HepB with 1018 adjuvant (HBsAg-1018) for improved seroprotection, and targeted and universal HepB vaccination reduced HBV infection Suggestive evidence indicated that targeted vaccination decreased the rate of hepatitis B surface antibody positivity and booster doses increased seroprotection in people aged 10-20. Weak evidence suggests potential local/systemic reaction risk with nucleotide analogs or HBsAg-1018. Convincing evidence shows HLA-DPB1*04:01 and DPB1*04:02 increased, while DPB1*05:01 decreased, hepatitis B antibody response. Obesity may reduce HepB seroprotection, as highly suggested.CONCLUSIONTargeted vaccination could effectively reduce HBV infection, and adjuvant and booster vaccinations enhance seroprotection without significant reaction. Factors such as obesity and genetic polymorphisms may affect the efficacy.

01 Oct 2024·American Journal of Gastroenterology

Utility of a Third Heplisav-B Dose in Patients With Inflammatory Bowel Disease Without Immunity After 2-Dose Heplisav-B Vaccination

Article

Author: Kwon, Joshua Y. ; Black, Cecily N. ; Picco, Michael F. ; Kinnucan, Jami A. ; Hashash, Jana G. ; Crosby, Sheena K. ; Caldera, Freddy ; Farraye, Francis A. ; Cortes, Pedro ; Karime, Christian

INTRODUCTION:Hepatitis B virus (HBV) vaccination is recommended in patients with inflammatory bowel disease (IBD). Although the 2-dose Heplisav-B vaccine has proven effective, more than 20% of patients with IBD do not seroconvert. We prospectively evaluated the effectiveness of a third Heplisav-B dose in patients with IBD lacking HBV immunity despite 2-dose vaccination.METHODS:Adults with IBD who had received 2-dose Heplisav-B vaccination between 2018 and 2023 were identified. Seroconversion was defined as hepatitis B surface antibody (HBsAb) ≥ 10 IU/L measured at ≥4 weeks after vaccination. Patients who did not seroconvert were prospectively offered a third Heplisav-B dose, followed by repeat HBsAb measurement. Demographic, clinical, medication, and vaccination data were compared between those who did and did not seroconvert.RESULTS:Of 192 patients identified, 71.9% (138/192) seroconverted after 2-dose Heplisav-B vaccination. The 54 patients (28.1%) who did not seroconvert were more likely to be male, have diabetes, chronic kidney disease, or elevated Charlson Comorbidity Index. Of the 54 patients, 30 (55.6%) elected to receive a third Heplisav-B dose, with 56.7% (17/30) achieving seroconversion (median HBsAb titer 376 IU/L, IQR 47–1,000 IU/L) despite a median intervaccination time of 416 days (IQR 90.8–667.8). No differences were noted between patients who did vs did not seroconvert after third-dose vaccination.DISCUSSION:In patients with IBD lacking HBV immunity despite 2-dose Heplisav-B vaccination, administration of a third dose resulted in a 56.7% seroconversion rate. Our results suggest that administration of an additional Heplisav-B dose may be an effective strategy in patients lacking immunity despite primary 2-dose vaccination.

01 Sep 2024·Clinical Transplantation

Hepatitis B Vaccine Compliance, Serologic Response, and Durability in Adult Thoracic Organ Transplant Recipients

Article

Author: Brumble, Lisa M. ; Beam, Elena ; Sampathkumar, Priya ; Vikram, Holenarasipur R. ; Chiu, Chia‐Yu ; Watt, Kymberly D.

ABSTRACTIntroductionHepatitis B virus (HBV) vaccination is recommended for solid organ transplant (SOT) candidates. However, there is a lack of data on the HBV vaccine compliance, serologic response, and durability of HBV seroprotection in thoracic organ transplantation recipients.MethodsWe conducted a retrospective study of adult thoracic organ (heart and lung) transplant candidates who received HBV vaccination at Mayo Clinic sites in Minnesota, Arizona, and Florida between January 2018 and August 2023. Conventional recombinant hepatitis B vaccine (Recombivax HB) was used before 2020, and Heplisav‐B was preferred after 2020. HBV seroprotection was defined as hepatitis B surface antibody (HBsAb) ≥ 10 IU/L. Furthermore, we compared characteristics between recipients who maintained HBV seroprotection and those who lost HBV seroprotection (HBsAb < 10 IU/L) at 30 days posttransplantation (D30).ResultsAmong 922 candidates who were eligible for HBV vaccination, 430 (47%) completed the HBV vaccine series. Patients receiving Heplisav‐B were more likely to complete the series than Recombivax HB (81% vs. 60%, p < 0.001) and Heplisav‐B had a higher seroprotection rate than Recombivax HB (75% vs. 64%, p = 0.023). Multivariate logistic regression analysis identified receiving Heplisav‐B as an independent predictor for HBV seroprotection (adjusted odds ratio [aOR] 1.723; 95% confidence interval [CI] 1.056–2.810; p = 0.029). A total of 145 thoracic organ transplant recipients achieved HBV seroprotection at the date of transplantation. Loss of HBV seroprotection occurred in 38 (26%) patients at D30. Multivariate logistic regression analysis identified two predictors for HBV seroprotection loss at D30: age ≥ 60 years (aOR, 2.503; 95% CI 1.026–6.107; p = 0.044), and pretransplant HBsAb level between 10 and 100 IU/L (aOR, 18.575; 95% CI 5.211–66.209; p < 0.001).ConclusionsAlthough less than half of thoracic organ transplant candidates completed HBV vaccine series pretransplant, Heplisav‐B provided a higher vaccine completion rate and seroprotection than the 3‐dose Recombivax HB. Clinicians should also be aware of the increased loss of HBV seroprotection in thoracic organ transplant recipients with age ≥ 60 years and pretransplant HBsAb between 10 and 100 IU/L. Assessment of seroprotection after HBV vaccination should be prioritized during the pretransplant period.

News (Medical) associated with Adjuvanted Hepatitis B vaccine (Recombinant)(Dynavax Technologies Corp.)

03 Dec 2024

·www.globenewswire.com

ACTG Announces Publication of BEe-HIVe Trial in JAMA

Data demonstrate superiority of HepB-CpG vaccination over conventional hepatitis B vaccines among people living with HIVLOS ANGELES, Dec. 03, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the publication of “HepB-CpG vs HepB Vaccine in People with HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial” in JAMA. The publication reports that two- and three-dose regimens of HepB-CpG vaccine provided superior protection compared to three doses of the conventional hepatitis B vaccine among people living with HIV who had previously not responded to the conventional vaccines. Hepatitis B is a leading cause of liver-related mortality worldwide resulting in more than 1 million deaths in 2022. It is a major cause of liver injury, cirrhosis, and liver cancer among people living with HIV, who often do not develop protective antibodies after receiving conventional hepatitis B vaccines. The HepB-CpG (HEPLISAV-B® [Hepatitis B Vaccine (Recombinant) Adjuvanted]) vaccine includes a TLR-9 agonist adjuvant (CpG 1018® adjuvant) and is known to achieve high protection against hepatitis B among people living with HIV, but until now there have been limited data about its protection among people living with HIV who had not responded to conventional hepatitis B vaccines. “These findings are tremendous news for people living with HIV who have struggled to achieve protection against hepatitis B,” said ACTG Chair Joseph J. Eron, M.D., University of North Carolina. “As a result of this data, the U.S. Department of Health and Human Services’ ‘Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV’ have been updated and clinical practice is already changing. Ultimately, we expect them to have an important impact on people living with HIV.” BEe-HIVe (B-Enhancement of HBV Vaccination in Persons Living With HIV, also known as A5379) was an international study evaluating the HepB-CpG vaccine among people living with HIV who were on antiretroviral therapy (ART) and had not responded to prior conventional hepatitis B vaccination and thus remained vulnerable to hepatitis B infection. This phase 3 randomized, open-label clinical trial included 561 people from 41 sites in 10 countries in Africa, Asia, North America, and South America. Study participants were equally randomized to one of three groups, receiving either: Two doses of HepB-CpG intramuscularly at week 0 and week 4Three doses of HepB-CpG intramuscularly at week 0, week 4, and week 24Three doses of HepB-alum (conventional hepatitis B vaccine) intramuscularly at week 0, week 4, and week 24 The primary analysis published in JAMA demonstrates that 99 percent of those receiving three doses of the HepB-CpG vaccine and 93 percent of those receiving two doses of the HepB-CpG vaccine achieved protection against hepatitis B compared to 81 percent receiving three doses of the conventional hepatitis B vaccine. The study demonstrates that the three-dose regimen of the HepB-CpG vaccine led to higher levels of protective antibodies, which may have long-term implications related to vaccine durability. Long-term protection results will be available in 2025. There were no unexpected safety concerns. “This study provides strong evidence that people living with HIV for whom prior hepatitis B vaccination was not successful should be re-vaccinated with the HepB-CpG vaccine to reduce their risk of future hepatitis B infection," said lead author and Protocol Co-Chair Kristen Marks, M.D., Weill Cornell Medicine. BEe-HIVe is led by Kenneth Sherman, M.D., Ph.D., University of Cincinnati and Massachusetts General Hospital (Protocol Chair) and Dr. Marks. ACTG is led by Dr. Eron and Rajesh T. Gandhi, M.D., Massachusetts General Hospital and Harvard Medical School (ACTG Vice-Chair). It is sponsored by the National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID, which also funds ACTG) under award numbers UM1 AI068636, UM1 AI107716, and UM1 AI068634. HEPLISAV-B® was provided by Dynavax Technologies Corporation. For more information about BEe-HIVe, please visit clinicaltrials.gov. About ACTG ACTG is the world’s largest and longest running clinical trials network focused on HIV and other infectious diseases and the people living with them. It is funded by NIAID and collaborating NIH Institutes. Founded in 1987, ACTG conducts research to improve the management of HIV and its comorbidities; develop a cure for HIV; and innovate treatments for tuberculosis, hepatitis B, and emerging infectious diseases. It comprises thousands of dedicated researchers, staff, and community members who are pursuing research into novel treatments and cures for infectious diseases at 65 locations across four continents, with the ultimate goal of advancing science that meaningfully impacts the lives of the people we serve. Disclaimer: This content is solely the responsibility of ACTG and does not necessarily represent the official views of the NIH. Media Contact:Jenna Conley, ACTGjenna@conleycommunications.net

Clinical ResultVaccinePhase 3

26 Nov 2024

·www.prnewswire.com

Dynavax to Present at the 7th Annual Evercore HealthCONx Conference

EMERYVILLE, Calif., Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. ET. The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at . About Dynavax Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit . For Investors/Media: Paul Cox [email protected] 510-665-0499 Nicole Arndt [email protected] 510-665-7264 SOURCE Dynavax Technologies WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccineDrug Approval

11 Nov 2024

·www.prnewswire.com

Dynavax Announces $100 Million Accelerated Share Repurchase Program

EMERYVILLE, Calif., Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock. Dynavax executed the ASR as part of the $200 million share repurchase program authorized by its Board of Directors in November 2024. Upon completion of this ASR, Dynavax will have $100 million remaining under the program. "Today's announcement of the accelerated share repurchase program reinforces our confidence in our business and our commitment to deliver value to our shareholders through our disciplined and thoughtful approach to capital allocation. We believe that our commercial success and financial position gives us the ability to strategically deploy capital, execute on our business strategy and invest in our long-term growth," said Kelly MacDonald, Chief Financial Officer of Dynavax. "We remain committed to leveraging our $200 million share repurchase program to create value for our shareholders through our balanced capital allocation strategy." Under terms of the agreement, Dynavax will pay $100 million to Goldman Sachs & Co. LLC and will initially receive approximately 6.1 million shares, with an aggregate value representing approximately 80% of the $100 million paid to Goldman Sachs & Co. LLC based on the $13.01 closing stock price of Dynavax's common stock on November 8, 2021. The final number of shares repurchased under the ASR will be based on the volume-weighted average prices of Dynavax's common stock during the term of the ASR, and subject to adjustments related to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed in the first quarter of 2025. As of November 5, 2024, Dynavax had approximately 131.5 million shares outstanding. About Dynavax Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit . Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements. Forward-looking statements can generally be identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "intend," "will," "may," "plan," "project," "potential," "seek," "should," "think," "toward," "will," "would" and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding our ability to execute on our strategic objectives, the anticipated benefits of our share repurchase program and the expected timing for completion of the ASR transaction. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including, the risk that our share repurchase program may not provide the benefits anticipated, as well as other risks detailed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the three months ended September 30, 2024 and periodic filings made thereafter, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at is not incorporated by reference in our current periodic reports with the SEC. For Investors/Media: Paul Cox [email protected] 510-665-0499 Nicole Arndt [email protected] 510-665-7264 SOURCE Dynavax Technologies WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Vaccine

100 Deals associated with Adjuvanted Hepatitis B vaccine (Recombinant)(Dynavax Technologies Corp.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BC	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis D	LI	Dynavax GmbH	18 Feb 2021
Hepatitis D	IS	Dynavax GmbH	18 Feb 2021
Hepatitis D	NO	Dynavax GmbH	18 Feb 2021
Hepatitis D	EU	Dynavax GmbH	18 Feb 2021
Hepatitis B	US	Dynavax Technologies Corp.	09 Nov 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	US	Dynavax Technologies Corp.	14 Dec 2020
HIV Infections	Phase 3	HT	Dynavax Technologies Corp.	14 Dec 2020
HIV Infections	Phase 3	KE	Dynavax Technologies Corp.	14 Dec 2020
HIV Infections	Phase 3	BR	Dynavax Technologies Corp.	14 Dec 2020
HIV Infections	Phase 3	MW	Dynavax Technologies Corp.	14 Dec 2020
HIV Infections	Phase 3	VN	Dynavax Technologies Corp.	14 Dec 2020
HIV Infections	Phase 3	UG	Dynavax Technologies Corp.	14 Dec 2020
Kidney Failure, Chronic	Discovery	DE	Dynavax Technologies Corp.	01 Dec 2010
Chronic Kidney Diseases	Discovery	US	Dynavax Technologies Corp.	01 Sep 2009
Hepatitis B	Discovery	CA	Dynavax Technologies Corp.	01 Dec 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03934736 (CTgov)	Phase 1	Kidney Failure, Chronic	119	HEPLISAV-B®	ekomhzcbnz(fjwgprbpzo) = dsgkklggqc gcphgzxvhk (tftyxaoere, wstxhcuvrp - oixvdvnmqd)	-	09 Aug 2024
NCT04456504 (CTgov)	Phase 4	Hepatitis B	49	Recombinant hepatitis B vaccine	wawsahgzit(glvivksruf) = dkhhqifmcc auxhcccubm (yvbzuhupys, pzhozmgpcr - abipyvukoa) View more	-	03 Jul 2024
NCT03685708 (CTgov)	Phase 2	Chronic Lymphocytic Leukemia \| Hepatitis B	78	HEPLISAV-B (Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib)	exnuvkptai(pnqiulinbv) = vtiypeqvfs pwboqkgsny (ylrshnmaaz, jteloceelx - wpdvesldtf) View more	-	15 Dec 2021
				HEPLISAV-B (Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib)	exnuvkptai(pnqiulinbv) = jimcuoyfml pwboqkgsny (ylrshnmaaz, kubtacpfqa - mvkxmlkmxi) View more
NCT00985426 (CTgov)	Phase 3	Chronic Kidney Diseases	521	Placebo+HEPLISAV-B (HEPLISAV-B)	thnljzdyhx(gbemtszsbs) = htnjghqqtk cghdjtzyft (oeqbfqiuia, hzcgvtpeqr - vnbjvympee) View more	-	16 Dec 2020
				Engerix-B (Engerix-B)	thnljzdyhx(gbemtszsbs) = afrowqpgju cghdjtzyft (oeqbfqiuia, bchummzxus - nbmdvlugdm) View more
ASN2018	Phase 3	anti-HBs levels	-	Heplisav-B	lvwqyonhmh(nvytartncm) = doisidlhly bqipjbeqyo (yvbdyfqkds )	Positive	23 Oct 2018
				Heplisav-BEngerix-BB (Engerix-B)	lvwqyonhmh(nvytartncm) = aftfbbcoyp bqipjbeqyo (yvbdyfqkds )
NCT00435812 (CTgov)	Phase 3	Hepatitis B	2,428	HEPLISAV and/or Placebo (HEPLISAV and/or Placebo)	whyhfvjsph(bcvjfcnlly) = evtylzjusy xuqryldhoq (zghofhodta, hqduvtsnyj - ajajkfgfzk) View more	-	13 Feb 2018
				Engerix-B (Engerix-B)	whyhfvjsph(bcvjfcnlly) = fpalwcvywq xuqryldhoq (zghofhodta, yapcitsxfk - utrijwizpv) View more
NCT02117934 (Pubmed) Manual	Phase 3	Hepatitis B	8,374	HBsAg-1018	kweqypfgxn(ymjjvbhvrr) = caoytjydtf pmkjmjhawn (drauqbnoql )	Superior	29 Jan 2018
				Engerix-B	kweqypfgxn(ymjjvbhvrr) = lugzffubgk pmkjmjhawn (drauqbnoql )
NCT01005407 (CTgov)	Phase 3	Hepatitis B	2,452	HEPLISAV and/or Placebo (HEPLISAV and/or Placebo)	pmbdiloguu(bycmglelwn) = eqnqshjfrf rfdqayebeh (gtnqnttqif, vavfopcxso - gussgqovbo) View more	-	11 Jan 2018
				Engerix-B (Engerix-B(1))	pmbdiloguu(bycmglelwn) = fmguvkhwfz rfdqayebeh (gtnqnttqif, zzbviiyfgl - skyodmbvri) View more
NCT02117934 (CTgov)	Phase 3	Hepatitis B	8,374	HEPLISAV (HEPLISAV)	tyeyttmtud(fawlqnqbtw) = kgpsjquooj xvbbcgocxt (omozszcwov, ajxchfvvyr - bedbkepbyj) View more	-	10 Jan 2018
				Engerix-B (Engerix-B)	tyeyttmtud(fawlqnqbtw) = outwkocuya xvbbcgocxt (omozszcwov, ytrtgkyjxm - zpkikcevuv) View more
NCT00511095 (CTgov)	Phase 2	Hepatitis B	207	HEPLISAV	bxvdyzxfgs(rnwzpbfmog) = ncbbnesffy agtfztjcjo (hshazshzcw, zjxdewjlso - syfaciiicg) View more	-	12 Apr 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Adjuvanted Hepatitis B vaccine (Recombinant)(Dynavax Technologies Corp.)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation